Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences reports recurring developments as an eyecare technology company developing and commercializing interventional ophthalmic devices for glaucoma and dry eye disease. Its news commonly covers financial results and guidance, segment trends in Interventional Glaucoma and Interventional Dry Eye, and clinical data for the OMNI Surgical System and TearCare System.
Company updates also address investor conference participation, intellectual property matters involving interventional glaucoma patents, and product positioning across minimally invasive glaucoma surgery and evaporative dry eye treatment. News about SGHT centers on commercialization, reimbursement-sensitive procedure adoption, clinical evidence, and operating performance in its ophthalmic device portfolio.
Sight Sciences (Nasdaq: SGHT) reported second quarter 2026 revenue of $23.4 million, up 20% year over year, with Interventional Glaucoma at $20.7 million (+8%) and record Interventional Dry Eye at $2.7 million (+704%). Gross profit was $21.4 million and reported gross margin 91%, or 86% excluding a $1.4 million tariff refund benefit.
Total operating expenses fell 11% to $25.3 million, and net loss improved to $4.4 million from $11.9 million, with net loss per share of $0.08. Cash and cash equivalents were $79.8 million with total long-term debt of $40.0 million; cash usage declined 28% to $5.2 million, or $1.4 million excluding non-recurring items. The company raised its full-year 2026 revenue guidance to $88–$92 million and lowered adjusted operating expense guidance to $92–$94 million. Additional highlights included expanded reimbursement and coverage for its glaucoma and dry eye procedures, and FDA 510(k) clearance for the OMNI Ultra Surgical System.
Sight Sciences (Nasdaq: SGHT) announced that Aetna’s updated Glaucoma Surgery Policy for commercial plans now recognizes the OMNI Surgical System and SION Surgical Instrument as medically necessary for treating mild-to-moderate open-angle glaucoma when specified clinical criteria are met.
The policy, retroactive to July 14, 2026, establishes coverage of Sight Sciences’ implant-free, minimally invasive glaucoma surgery technologies, including ab interno canaloplasty (e.g., OMNI) and adult goniotomy (e.g., SION). Aetna covers approximately 25 million total commercial lives in the U.S.
Sight Sciences (Nasdaq: SGHT) received FDA 510(k) clearance for its OMNI Ultra Surgical System for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. OMNI Ultra is the first FDA-cleared MIGS device enabling circumferential canaloplasty in a single pass.
The system adds TruSync Plus technology for controlled viscodilation, preserves the implant-free design, and targets all three conventional outflow resistance sites. According to Sight Sciences, more than 350,000 OMNI procedures have been performed worldwide, and U.S. commercial launch of OMNI Ultra is planned for the fourth quarter of 2026.
Sight Sciences (Nasdaq: SGHT) will report its financial results for the second quarter ended June 30, 2026, after the market close on Wednesday, August 5, 2026. Company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible via live and archived webcast on the Investors section of the Sight Sciences website, with replay available for at least 90 days.
Sight Sciences (Nasdaq: SGHT) reported Q1 2026 revenue of $19.7M (+13% Y/Y), with Interventional Glaucoma at $18.3M and Interventional Dry Eye at $1.4M (up 244% Y/Y). Gross margin was 86%. Q1 net loss was $13.0M (−$0.24 per share). Cash totaled $85.0M and long-term debt was $40.0M as of March 31, 2026. The company raised 2026 revenue guidance to $83.0M–$89.0M and reaffirmed adjusted operating expense guidance of $93.0M–$96.0M. A Delaware court awarded $55.4M plus a 10% ongoing royalty in a patent judgment, subject to appeal.
Sight Sciences (NASDAQ: SGHT) will present at two investor conferences in May 2026: the BofA Securities 2026 Health Care Conference in Las Vegas on May 13, 2026 at 3:15 pm PT / 6:15 pm ET, and the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026 at 9:00 am PT / 12:00 pm ET.
According to Sight Sciences, interested parties can access live and archived webcasts via the company’s Investors website.
Sight Sciences (NASDAQ: SGHT) published its third annual Sustainability Report on April 22, 2026, covering 2023–2025 environmental, social, and governance activities. Key figures include donations to 24 programs in 24 countries, a reported >20% reduction in Scope 1–3 emissions in 2025, and a workforce of 187 with 56% women.
The report details energy and waste initiatives, emissions reporting, community programs, pay equity, employee development, and governance oversight by the Nominating and Corporate Governance committee.
Sight Sciences (Nasdaq: SGHT) said it will report first quarter 2026 financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026.
Management will review the results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the company Investors page, with replay accessible for at least 90 days.
Sight Sciences (Nasdaq: SGHT) announced clinical data presentations for its OMNI Surgical System and TearCare System at the 2026 ASCRS Annual Meeting in Washington, DC on April 11. According to the company, OMNI data show reduced long-term diurnal IOP fluctuations regardless of lens status, while TearCare data report early and sustained superiority over Restasis for tear film stability.
Presentations include TearCare oral and poster sessions on April 11 and an OMNI poster on longer-term diurnal IOP following canaloplasty and trabeculotomy; lead and presenting authors are named.
Sight Sciences (Nasdaq: SGHT) will present at the 25th Annual Needham Healthcare Conference on Monday, April 13, 2026 at 11:15 am PT / 2:15 pm ET. Management will deliver a fireside chat available via live and archived webcast.
Investors can access the webcast on the company’s Investors website for a live stream and later replay.